On September 5, 2023 Beactica Therapeutics AB, the Swedish precision oncology company, reported the selection of BEA-17 as a preclinical candidate for its LSD1 programme aimed at finding new therapies for aggressive brain tumours and other life-threatening cancers (Press release, Beactica, SEP 5, 2023, View Source [SID1234634920]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BEA-17 is a first-in-class small molecule which has shown promising potentiation of immune-modulating treatments in preclinical models of several cancer forms. BEA-17 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of glioblastoma (GBM), the most aggressive form of brain tumour. With the selection of this first preclinical candidate, IND-enabling toxicology studies will be initiated in preparation for clinical trials.

"We are thrilled to announce the selection of BEA-17 as a preclinical candidate. Reaching this remarkable milestone is a major achievement, as the vast majority of programmes fail at the preclinical stage." said Dr Per Källblad, CEO of Beactica Therapeutics. "The selection of this molecule reflects our aim to test this new approach in humans as quickly as possible."

About BEA-17

BEA-17 is a first-in-class small molecule targeted degrader (non-PROTAC) of lysine demethylase 1 (LSD1) and its co-factor CoREST. In syngeneic animal models of cancer, the compound has shown promising potentiation of immune-modulating treatments in several cancer forms, including anti-PD1 checkpoint inhibitors in colon cancer (CT26) and standard of care (temozolomide and radiation) in glioblastoma (GL261). Pharmacokinetic studies of BEA-17 show good blood-brain-barrier penetration and oral availability. BEA-17 is investigational and not approved anywhere globally. Its efficacy and safety in humans have not been established. BEA-17 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of glioblastoma (GBM).